Switch to:
More From Other Websites
[$$] Gilead Cancer Treatment Fails Sep 17 2014
6:01 am Gilead Sciences announces data from Phase 2 study of Simtuzumab for previously untreated... Sep 17 2014
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer Sep 17 2014
Gilead Sciences Sep 16 2014
Today's Market Thorns, Roses, and All Time Highs... Sep 16 2014
Stocks Rise Ahead Of Fed, Led By Biotech, Chip Names Sep 16 2014
Gilead (GILD) Slips on Generic Sovaldi Licensing Deals Sep 16 2014
Gilead Up As Analyst Lifts Sovaldi Q3 Estimate Sep 16 2014
[$$] Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries Sep 16 2014
Gilead Sciences: Another Analyst Lifts Sovaldi Forecast Sep 16 2014
Stock Futures Mildly Lower; Netflix, Gilead Still Sliding Sep 16 2014
Hitachi, Gilead, Amazon, Facebook: Intellectual Property Sep 15 2014
Gilead slashes cost of $1,000-a-pill hepatitis drug for poor nations Sep 15 2014
$1,000-a-pill hep C treatment to be cheaper abroad Sep 15 2014
Biotech still place to be: Pro Sep 15 2014
Gilead shares drop as plan emerges to discount Sovaldi in poorer regions Sep 15 2014
Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism Sep 15 2014
[video] Gilead Expands Access of Hepatitis C Drug in Developing Countries Sep 15 2014
Gilead will license cheaper, generic version of Sovaldi Sep 15 2014
Gilead in deal with India labs to produce Sovaldi Sep 15 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK